Niraparib with pembrolizumab maintenance therapy for metastatic stage III or IV non-small cell lung cancer

Niraparib with pembrolizumab is in clinical development for the maintenance therapy of patients with later stages of non-small cell lung cancer (NSCLC) after first-line platinum-based chemotherapy with pembrolizumab. Lung cancer is the third most common cancer in the UK and about 47,000 people are diagnosed with it each year. When cancer starts in the lungs, it is called primary lung cancer and when the cancer cells spread from the lungs to other organs, it is referred to as metastatic lung cancer. There are different kinds of lung cancer including NSCLC which is the most common type; it grows slowly and has often spread to other parts of the body by the time it is diagnosed. Some symptoms include a cough, repeated chest infections, breathlessness, unexplained pain, weight loss or tiredness.